Vaccines Based on Dendritic Cells: Breaking Barriers to New Immune Response Approach

Dear Colleagues,

Dendritic cells (DCs) are versatile cells that bridge the gap between innate and adaptive immune responses. They are potent antigen-presenting cells that control both T cell immunity and tolerance. DCs are often downregulated in diseases such as cancer, where they are called tolerogenic DCs and have a crucial role in inducing peripheral tolerance. As a result, DCs have been successfully targeted using inhibitory drugs or DC-based vaccines as immunotherapies. These therapies are often employed as a second-line treatment after traditional therapies prove ineffective. DC vaccines have a significant role in preventing relapses and metastasis post tumor treatment. Recent studies on vaccines based on nucleic acids such as DNA or mRNA have shown remarkable results in treating diseases such as COVID-19 and multiple solid tumors. We invite contributions of original reports, observations, or reviews to highlight (i) their role in preventing relapses in cancer, (ii) the metabolic signaling pathway target, (iii) the ability to cross the blood–brain barrier in pathological processes or as a vaccination strategy, and (iv) recent advances in novel therapeutic vaccines based on dendritic cells.

Prof. Dr. Soledad Lopez-Enriquez
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• plasmacytoid dendritic cells
• myeloid dendritic cells
• immunotolerance
• regulatory T cells
• cytotoxic T cells
• NK cells
• immunotherapies
• nanovaccines
• immunometabolism
• delivery systems